Interstate Prescribing for Ketamine: Can Your Provider Be in Another State?

One of the most common questions from patients exploring telehealth ketamine is whether it matters where their provider is physically located. The answer involves federal controlled substance law, state licensing requirements, and practical considerations about how telehealth platforms operate.

The Core Rule: License in the Patient's State

The governing principle of telehealth medical practice is that a provider must be licensed in the state where the patient is located—not where the provider is sitting. This applies regardless of whether the consultation is in person or via telehealth.

If you are in Texas and your provider is physically in New York, that provider must hold a Texas medical license (or NP or PA license, depending on their credentials) to legally evaluate and treat you. The physical location of the provider is essentially irrelevant to this requirement.

This is why telehealth ketamine platforms cannot operate universally—they are limited to states where their providers hold licenses.

DEA Registrations and Interstate Prescribing

In addition to state licensure, prescribing controlled substances requires a DEA registration. DEA registrations are tied to a specific practice address but are not inherently limited to a single state—a provider can hold one DEA registration and prescribe to patients in multiple states, as long as they hold the appropriate medical license in each state where patients are located.

This is an important distinction: state medical licensure is the primary geographic constraint on telehealth ketamine access, not the DEA registration structure.

The Interstate Medical Licensure Compact (IMLC)

The Interstate Medical Licensure Compact is a significant development that has expanded telehealth physician access across state lines. The IMLC is an agreement among member states that creates an expedited pathway for physicians to obtain licenses in additional states. Physicians already licensed in one IMLC member state can apply for licenses in other member states through a streamlined process.

As of 2025, more than 40 states have joined the IMLC. This means physicians in IMLC states can obtain multi-state licenses more easily, which has enabled telehealth platforms to expand their geographic footprint significantly.

Key Points About the IMLC

It applies to physicians (MDs and DOs). The IMLC does not apply to nurse practitioners or physician assistants, who have their own separate compacts.

Nurse Licensure Compact (NLC): Many NPs hold multi-state licenses through the NLC, which covers nursing licensure across approximately 40 participating states. This is relevant because many telehealth ketamine providers use NPs as prescribers.

Physician Assistant Licensure Compact (PALC): A newer compact for PAs that is growing in membership, facilitating multi-state PA practice.

How This Affects Telehealth Ketamine Access

In practice, the largest telehealth ketamine platforms employ providers licensed across multiple states using compact frameworks and targeted state licensure efforts. This allows them to serve patients in 25-40 states without patients needing to be concerned about their specific provider's physical location.

From the patient's perspective, what matters is not where your specific provider is, but whether the platform has providers licensed in your state who are available to take new patients.

Checking Availability

When evaluating a telehealth ketamine platform, confirm:

1. Does the platform currently accept patients from your state?
2. Are there providers available for new patient evaluations, or is there a waitlist?
3. Which type of provider (MD, NP, PA) will be prescribing, and are they licensed in your state? Our nurse practitioner prescribing guide explains how provider type affects your care.

Platforms should be able to confirm all three without difficulty. If a platform is vague about whether it serves your state, that is worth clarifying before investing time in an intake.

States Not Covered by Major Platforms

Some states are not covered by major telehealth ketamine platforms due to:

• The platform's providers not having licenses there
• State-specific regulatory requirements that make the platform's operating model impractical
• State compounding pharmacy rules that prevent medication shipping
• Low population density making the market economically unviable

Patients in uncovered states have options:

1. Seek a local in-person provider: IV ketamine clinics and in-person compounding ketamine programs exist in most states
2. Check smaller platforms: Some regional telehealth practices serve states that national platforms do not
3. Consult a psychiatrist: A psychiatrist may be willing to prescribe ketamine off-label as part of a treatment plan, which may be prescribable through a local compounding pharmacy

The Future of Interstate Telehealth Prescribing

The trend is toward greater interstate flexibility, not less. State medical boards increasingly recognize that telehealth medicine crosses state lines and that the patchwork of licensing requirements creates barriers to care. The growth of licensing compacts, the expansion of IMLC membership, and federal policy discussions around telehealth access all point toward a future where interstate prescribing is more standardized.

The DEA's permanent telemedicine prescribing framework, when finalized, will likely include provisions that acknowledge the multi-state nature of telehealth practice. How exactly this interacts with state licensing requirements will require time to develop.

For patients today, the practical message is: check your state first. If a major platform serves your state, you likely have access to providers regardless of where those providers are physically located. Our provider verification guide can help you confirm that any out-of-state provider is properly licensed. If your state is not served, explore the alternatives noted above.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service